2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Quantified Cell Binding of Astatinated Immunoconjugates on Ovarian Cancer Cell Spheroids by Alpha Camera Imaging

Ottawa, ON, Canada (UroToday.com) Due to the highly non-uniform distribution of radiation in tumors treated with alpha therapy, it is essential to understand the microdosimetry. The alpha camera is a very useful tool for determining the micro-distribution. The alpha camera works by placing a section of tissue on a piece of scintillator viewed by lensing system and quantum CCD camera. Individual alpha tracks are detected. The device can be operated in either an integrated or single-event format. Single event frames can be concatenated to form a “movie” of the alpha activity.

For the in vitro study, NIH-OCAR-3 ovarian cancer cells were treated with At211-MX35 and At211-Farletuzumab. Equilibrium binding was achieved after 4 hours followed by a decline due to cell death. The Farletuzumab results largely agreed with simulation predictions while the MX35 showed higher activity.


Presented by: Dr. Tom Back, Researcher, The University of Gothenburg, Sahlgrenska Academy

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada